Efficacy and safety of light therapy for Parkinson disease  

作　　者：Yanghong Li Xiaoxia Zhou Xinyin Wu Beisha Tang 

机构地区：[1]Department of Neurology,Xlangya Hospital,Central South University,Changsha,Hunan,China [2]Xlangya School of Public Health,Central South University,Changsha,Hunan,China [3]Department of Geriatric Neurology,Xiangya Hospital,Central South University,Changsha,Hunan,China [4]National Clinical Research Center for Geriatric Diseases(Xiangya),Changsha,Hunan,China

出　　处：《Chinese Medical Journal》2022年第7期878-880,共3页中华医学杂志（英文版）

基　　金：the National Natural Science Foundation of China(No.81430023)。

摘　　要：To the Editor:Parkinson disease(PD)is the second most common neurodegenerative disorder associated with significant disability and negative impact on quality of life(QoL),affecting 2%to 3%of the population≥65 years of age.^([1])Although the disorder is defined by motor features including asymmetric tremor,bradykinesia,and rigidity,various non-motor features are typically seen,including cognitive impairment,depression,sensory symptoms,autonomic dysfunction,and sleep disturbances.Due to the complexity,PD is challenging to treat.There are currently no effective treatments to prevent or halt the progression of PD.

关 键 词：IMPAIRMENT RIGIDITY typically 

分 类 号：R742.5[医药卫生—神经病学与精神病学]